āĻšā§‹āĻŽAPNHY â€ĸ OTCMKTS
Aspen Pharmacare Holdings ADR
ā§Ŧ.ā§­ā§Ŧ$
⧍ āĻŽā§‡, ā§Ž:ā§§ā§Ļ:ā§Ļā§Ļ PM GMT -ā§Ē · USD · OTCMKTS · āĻĄāĻŋāϏāĻ•ā§āϞ⧇āĻŽāĻžāϰ
āĻŽāĻžāĻ°ā§āĻ•āĻŋāύ āϝ⧁āĻ•ā§āϤāϰāĻžāĻˇā§āĻŸā§āϰ-āĻ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋZA-āĻ āĻšā§‡āĻĄāĻ•ā§‹ā§ŸāĻžāĻ°ā§āϟāĻžāϰ
āĻ•āĻžāϞ āĻļ⧇āώ āϝ⧇ āĻĻāĻžāĻŽā§‡ āĻ›āĻŋāϞ
ā§Ŧ.ā§Ļā§Ļ$
āϏāĻžāϰāĻž āĻĻāĻŋāύ⧇āϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ā§Ÿā§‡ āĻ¸ā§āϟāϕ⧇āϰ āĻĻāĻžāĻŽā§‡āϰ āĻ“āĻ āĻž āύāĻžāĻŽāĻžāϰ āϰ⧇āĻžā§āϜ
ā§Ŧ.ā§­ā§Ģ$ - ā§Ŧ.ā§­ā§Ŧ$
āϏāĻžāϰāĻž āĻŦāĻ›āϰ⧇āϰ āϰ⧇āĻžā§āϜ
ā§Ģ.ā§­ā§Ŧ$ - ā§§ā§Š.ā§Ŧ⧝$
āĻŽāĻžāĻ°ā§āϕ⧇āϟ āĻ•ā§āϝāĻžāĻĒ
ā§Ģā§Ģ.ā§Ģā§ĢāĻļāĻ¤Â āϕ⧋ ZAR
āĻ—āĻĄāĻŧ āĻ­āϞāĻŋāωāĻŽ
ā§§.ā§Ŧā§Ē āĻšāĻž
āĻŦāĻžāϜāĻžāϰ āϏāĻ‚āĻŦāĻžāĻĻ
.INX
ā§§.ā§Ēā§­%
āĻĢāĻžāχāύāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒāĻžāϰāĻĢāĻ°ā§āĻŽā§āϝāĻžāĻ¨ā§āϏ
āĻ†ā§Ÿā§‡āϰ āĻ¸ā§āĻŸā§‡āϟāĻŽā§‡āĻ¨ā§āϟ
āωāĻĒāĻžāĻ°ā§āϜāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
(ZAR)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĒY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āωāĻĒāĻžāĻ°ā§āϜāύ
ā§§ā§Ļ.ā§¯ā§ŽāĻļāĻ¤Â āĻ•ā§‹ā§Š.ā§Žā§­%
āĻŦā§āϝāĻŦāϏāĻž āϚāĻžāϞāĻžāύ⧋āϰ āĻ–āϰāϚ
ā§Šā§¨ā§­.⧝ā§Ļ āϕ⧋⧧⧍.ā§Žā§Ē%
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
⧧⧧⧝.ā§Ēā§Ļ āĻ•ā§‹ā§Š.⧍ā§Ļ%
āύ⧇āϟ āĻĒā§āϰāĻĢāĻŋāϟ āĻŽāĻžāĻ°ā§āϜāĻŋāύ
ā§§ā§Ļ.ā§Žā§­-ā§Ļ.ā§­ā§Š%
āĻļā§‡ā§ŸāĻžāϰ āĻĒā§āϰāϤāĻŋ āωāĻĒāĻžāĻ°ā§āϜāύ
——
EBITDA
⧍ā§Ēā§Ŧ.ā§­ā§Ģ āϕ⧋⧧⧧.ā§Ļā§Ģ%
āĻĒā§āϰāϝ⧋āĻœā§āϝ āĻŸā§āϝāĻžāĻ•ā§āϏ⧇āϰ āĻšāĻžāϰ
⧍ā§Ģ.ā§Ļ⧍%—
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
(ZAR)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĒY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āĻ•ā§āϝāĻžāĻļ āĻ“ āĻ•āĻŽ āϏāĻŽā§Ÿā§‡āϰ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—
ā§Ŧā§Žā§Ļ.ā§Ēā§Ļ āϕ⧋-ā§Ēā§§.ā§Šā§Š%
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
ā§§ā§Šā§Ŧ.ā§Ŧā§Ļāϕ⧋-ā§§.ā§¯ā§Š%
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
ā§Ģā§§.ā§Ģā§§āĻļāĻ¤Â āϕ⧋-ā§Ē.ā§Ļā§Ŧ%
āĻŽā§‹āϟ āχāϕ⧁āχāϟāĻŋ
ā§Žā§Ģ.ā§Ļ⧝āĻļāĻ¤Â āĻ•ā§‹â€”
āφāωāϟāĻ¸ā§āĻŸā§āϝāĻžāĻ¨ā§āĻĄāĻŋāĻ‚ āĻļā§‡ā§ŸāĻžāϰ
ā§Ēā§Ē.ā§Ēā§§Â āĻ•ā§‹â€”
āĻĒā§āϰāĻžāχāϏ āϟ⧁ āĻŦ⧁āĻ• āϰ⧇āĻļāĻŋāĻ“
ā§Ļ.ā§Ļā§Šâ€”
āϏāĻŽā§āĻĒāĻĻ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§Š.ā§Ģā§Ŧ%—
āĻŽā§‚āϞāϧāύ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§Ē.ā§Ļā§Ē%—
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
(ZAR)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĒY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
⧧⧧⧝.ā§Ēā§Ļ āĻ•ā§‹ā§Š.⧍ā§Ļ%
āĻ…āĻĒāĻžāϰ⧇āĻļāύ āĻĨ⧇āϕ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āĻ•ā§āϝāĻžāĻļ
⧝ā§Ļ.⧍ā§Ģ āϕ⧋-⧍ā§Ŧ.ā§Ģā§­%
āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
-ā§§ā§Šā§¯.ā§Ģā§Ģ āϕ⧋ā§Ģā§Ē.ā§­ā§Ŧ%
āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋāĻ‚ āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
ā§Ēā§­.⧝ā§Ģ āϕ⧋-ā§­ā§Ģ.ā§Ēā§Ģ%
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
-⧍ā§Ļ.ā§Žā§Ļ āϕ⧋-ā§Ē⧍⧭.ā§Ģā§Ŧ%
āĻĢā§āϰāĻŋ āĻ•ā§āϝāĻžāĻļ āĻĢā§āϞ⧋
ā§§ā§Ģ.ā§Ģā§Ļ āĻ•ā§‹ā§§ā§Žā§Ģ.⧝⧝%
āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§Ÿā§‡āϛ⧇
ā§§ā§Žā§Ģā§Ļ
āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ
āĻ•āĻ°ā§āĻŽāϚāĻžāϰ⧀
⧝,ā§§ā§Ļ⧝
āφāϰāĻ“ āĻĻ⧇āϖ⧁āύ
āφāĻĒāύāĻžāϰ āĻšā§ŸāϤ āĻĒāĻ›āĻ¨ā§āĻĻ āĻšāĻŦ⧇
āϏāĻŽā§āĻĒā§āϰāϤāĻŋ āĻ•āϰāĻž āϏāĻžāĻ°ā§āϚ, āĻĢāϞ⧋ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ•ā§āϟāĻŋāĻ­āĻŋāϟāĻŋ āĻĨ⧇āϕ⧇ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āĻœā§‡āύāĻžāϰ⧇āϟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ

āϏāĻŽāĻ¸ā§āϤ āĻĄā§‡āϟāĻž āĻ“ āϤāĻĨā§āϝ "āϝ⧇āĻŽāύāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϛ⧇, āĻ āĻŋāĻ• āϤ⧇āĻŽāύāĻ­āĻžāĻŦ⧇" āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĒā§āϰāĻĻāĻžāύ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻļā§‡ā§ŸāĻžāϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ, āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—, āĻŸā§āϝāĻžāĻ•ā§āϏ, āφāχāύāĻŋ āĻŦāĻŋāώ⧟, āĻ…ā§āϝāĻžāĻ•āĻžāωāĻ¨ā§āϟāĻŋāĻ‚ āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύāĻ“ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻŦāĻž āωāĻĒāĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āϤāĻž āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤ Google āϕ⧋āύāĻ“ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āωāĻĒāĻĻ⧇āĻˇā§āϟāĻž āύ⧟ āĻāĻŦāĻ‚ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϤ⧇ āĻ…āĻ¨ā§āϤāĻ°ā§āϭ⧁āĻ•ā§āϤ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋ āĻ…āĻĨāĻŦāĻž āϏ⧇āχāϏāĻŦ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋāϰ āχāĻ¸ā§āϝ⧁ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋāϰ āĻŦā§āϝāĻžāĻĒāĻžāϰ⧇ āϕ⧋āύāĻ“ āϰāĻ•āĻŽ āĻŽāϤāĻžāĻŽāϤ āĻŦā§āϝāĻ•ā§āϤ āĻ•āϰ⧇ āύāĻžāĨ¤ āϝ⧇āϕ⧋āύāĻ“ āϧāϰāύ⧇āϰ āĻŸā§āϰ⧇āĻĄ āĻ•āϰāĻžāϰ āφāϗ⧇, āĻŽā§‚āĻ˛ā§āϝ āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āύ⧇āĻ“ā§ŸāĻžāϰ āϜāĻ¨ā§āϝ āφāĻĒāύāĻžāϰ āĻŦā§āϰ⧋āĻ•āĻžāϰ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒā§āϰāϤāĻŋāύāĻŋāϧāĻŋāϰ āϏāĻžāĻĨ⧇ āφāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āύāĻŋāύāĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ
āϞ⧋āĻ•āϜāύ āĻāϗ⧁āϞāĻŋāĻ“ āĻ–ā§‹āρāĻœā§‡āύ
āϏāĻžāĻ°ā§āϚ āĻ•āϰ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŽā§āϛ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧁āύ
Google āĻ…ā§āϝāĻžāĻĒā§āϞāĻŋāϕ⧇āĻļāĻžāύāϗ⧁āϞāĻŋ
āĻĒā§āϰāϧāĻžāύ āĻŽā§‡āύ⧁